Sale

Diabetic Neuropathy Treatment Market

Global Diabetic Neuropathy Treatment Market Share, Trends, Growth, Analysis, Insights, Forecast: By Disease Type: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy; By Treatment Method: Drugs, Others; By End User; By Treatment Channel; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032

Global Diabetic Neuropathy Treatment Market Outlook

The global diabetic neuropathy treatment market is driven by the rising number of hyperglycaemia cases, which was nearly 569.59 million in 2023. The prevalence of the hyperglycaemia is likely to grow at a CAGR of 3% during the forecast period of 2024-2032 to reach approximately 743.19 million cases by 2032.

 

diabetic neuropathy treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Introduction

Diabetic neuropathy is a condition that causes nerve damage in people with diabetes. Nerves are damaged by high blood sugar in diabetics, resulting in diabetic neuropathy. 

 

Legs and feet are the most severely affected body parts in this condition. 

 

There are also symptoms associated with neuropathy, such as pain and numbness, depending on the nerves affected, such as peripheral nerves, autonomic nerves, proximal nerves, and focal nerves. 

 

Following are the different types of diabetic neuropathy:

  • Peripheral Neuropathy- Affects legs and feet.
  • Autonomic Neuropathy- Affects the digestive system, primarily the stomach.
  • Proximal Neuropathy- Affects buttocks and thighs.

 

Worldwide, diabetes treatment is considered a top priority. It is not possible to cure neuropathic changes or provide pain relief with a single treatment. Various approaches are used to manage diabetic neuropathy, including intensive glucose control, treatment of risk factors, and treatment based on pathogenetic mechanisms.

 

The rapidly rising number of diabetic neuropathies and increased awareness in the next few years will compel major companies to launch new products. Thus, key players in the market are developing technologically advanced products to gain a competitive edge.

 

According to the global diabetic neuropathy treatment market research report, the market can be categorised into the following segments: 

 

diabetic neuropathy treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Disease Type

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

 

Market Breakup by Treatment Method

  • Drugs
    • Analgesics
    • Antidepressant
    • Anticonvulsants
    • Others
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Non-Steroidal Anti-Inflammatory Drugs
  • Others

 

Diabetic Neuropathy Treatment Market Breakup by End-User

  • Hospitals And Clinics
  • Retail Pharmacy
  • Online Pharmacy

 

Market Breakup by Treatment Channel

  • Public
  • Private

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

diabetic neuropathy treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Prevalence of Diabetes to Drive the Diabetic Neuropathy Treatment Market Growth

The steep rise in diabetes cases will impact the growth of the market during the forecast period. The complications related to diabetes, cardiovascular diseases, obesity, and other complications related to glucose control contribute to neuropathy development. This includes the development of new products by manufacturers that are effective at treating neuropathy. 

 

Additionally, increased urbanization is causing unhealthy lifestyles like unhealthy food consumption, sedentary living, and others that adversely affect the market growth.

 

Other factors driving the growth of the diabetic neuropathy treatment market include ageing population, growing health care facilities, and increasing health care costs. 

 

Market Growth to be Hindered by the High Price of the Product and the Availability of Alternatives for Diabetic Neuropathy

Diabetes neuropathy drugs are becoming increasingly expensive, and alternative treatments for the condition are also available readily available. These factors are hindering the growth of the global market. 

 

Availability of alternative treatments, such as radiotherapy and physical therapy, that may improve patient outcomes, is also obstructing the growth of the market. Other factors that could hamper the market growth include regulations, product recalls, and FDA approval delays.

 

Regional Outlook for the Diabetic Neuropathy Treatment Market

The increasing diabetes prevalence and incidence cases make North America a major regional market. Various factors contribute to the growth of the market, such as early adoption of drugs, availability of advanced therapies, and the availability of combination drugs. 

 

It is estimated that the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to the high prevalence of diabetes, obesity, and cardiac arrhythmia-related issues, and government support for healthcare awareness and research activities.

 

Therapeutic Landscape

People with diabetes can be affected by diabetic neuropathy, a chronic debilitating condition. The objective assessment of diabetic neuropathy makes it difficult to diagnose and evaluate in clinical trials. Currently, there is no treatment available to prevent or reverse neuropathy or to relieve pain completely. 

 

Diabetic neuropathy could be treated with Nav 1.7 antagonists, calcium channel blockers, anti-NGF antibodies, and angiotensin II type 2 receptor antagonists.

 

As part of its neuropathic pain treatment program, Novartis AG introduced Tegerton (carbamazepine), a new epilepsy drug designed to reduce nerve impulses that cause pain in diabetics. 

 

Nucynta ER, a pain reliever derived from opioids, used to treat diabetes-induced nerve damage, was also launched by Janssen Pharmaceuticals. 

 

Among the recommended treatment options for diabetic neuropathy, there are antidepressants like amitriptyline and duloxetine as well as topical agents like gabapentin and pregabalin analogues and opioids for pain relief in neuropathy. 

 

In order to alleviate pain and improve quality of life associated with diabetic neuropathy, more research is needed on the most effective drugs or combinations. 

 

Clinical Trials

In current therapies, sensory deficits and aetiology are not addressed, so there is an unmet demand for treatment options that target the natural course of the condition. 

 

The outcomes of recent randomized controlled trials show that some of these pathological treatments improve neuropathic endpoints clinically. Patients with neuropathic pain remain undertreated with effective analgesic monotherapy as limited number of patients able to achieve clinically meaningful results. 

 

New pharmaceutical approaches have been expanded due to increased knowledge of neurobiology and phenotypic profiling of neuropathic pain. 

 

A number of promising molecular structures are in clinical development, which will soon improve our therapeutic arsenal of diabetic neuropathy treatments. 

 

In diabetic neuropathy, the disease progresses over time. Medication and lifestyle changes can alleviate this condition. Medications that control diabetes are the most effective in slowing the onset of complications caused by diabetes. 

 

The FDA has approved these drugs for treating diabetic neuropathy: 

  • anticonvulsant Lyrica (pregabalin)
  • antidepressant Cymbalta (duloxetine)
  • opioid Nucinta (tapentadol)

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global diabetic neuropathy treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

 

  • Novartis AG
  • Pfizer Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Eli Lilly and Company
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • Lupin Ltd
  • Depomed, Inc
  • Astellas Pharma Inc
  • Meda Pharma GmBH & Co. KG

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Treatment Method
  • End User
  • Treatment Channel
  • Region
Breakup by Disease Type
  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy
Breakup by Treatment Method
  • Drugs
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Non-Steroidal Anti-Inflammatory Drugs
  • Others
Breakup by End User
  • Hospitals And Clinics
  • Retail Pharmacy
  • Online Pharmacy
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Novartis AG
  • Pfizer Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Eli Lilly and Company
  • Abbott Laboratories 
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • GlaxoSmithKline Plc
  • Lupin Ltd
  • Depomed, Inc
  • Astellas Pharma Inc
  • Meda Pharma GmBH & Co. KG

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Diabetic Neuropathy Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Current Scenario Evaluation and Regulatory Framework
    6.1    Emerging Therapies and Clinical Trials Synopsis
    6.2    Patent Landscape
        6.2.1    Patent Overview
            6.2.1.1    Patent Status and Expiry
            6.2.1.2    Timelines from Drug Development to Commercial Launch
            6.2.1.3    New Drug Application
                6.2.1.3.1    Documentation and Approval Process
    6.3    Cost of Treatment
    6.4    Regulatory Framework
        6.4.1    Regulatory Overview
            6.4.1.1    US FDA
            6.4.1.2    EU EMA
            6.4.1.3    INDIA CDSCO
            6.4.1.4    JAPAN PMDA
            6.4.1.5    Others
7    Challenges and Unmet Needs
    7.1    Treatment Pathway Challenges
    7.2    Compliance and Drop-Out Analysis
    7.3    Awareness and Prevention Gaps
8    Global Diabetic Neuropathy Treatment Market
    8.1    Global Diabetic Neuropathy Treatment Market Overview
    8.2    Global Diabetic Neuropathy Treatment Market Analysis 
        8.2.1    Market Overview
            8.2.1.1    Global Diabetic Neuropathy Treatment Market Historical Value (2017-2023) 
            8.2.1.2    Global Diabetic Neuropathy Treatment Market Forecast Value (2024-2032)
    8.3    Global Diabetic Neuropathy Treatment Market by Disease Type
        8.3.1    Market Overview
            8.3.1.1    Peripheral Neuropathy 
            8.3.1.2    Autonomic Neuropathy
            8.3.1.3    Proximal Neuropathy 
            8.3.1.4    Focal Neuropathy
    8.4    Global Diabetic Neuropathy Treatment Market by Treatment Method
        8.4.1    Market Overview
            8.4.1.1    Drugs
                8.4.1.1.1    Analgesics 
                8.4.1.1.2    Antidepressant 
                8.4.1.1.3    Anticonvulsants 
                8.4.1.1.4    Others
            8.4.1.2    Transcutaneous Electrical Nerve Stimulation (TENS)
            8.4.1.3    Non-Steroidal Anti-Inflammatory Drugs
            8.4.1.4    Others
    8.5    Global Diabetic Neuropathy Treatment Market by End User
        8.5.1    Market Overview
            8.5.1.1    Hospitals And Clinics 
            8.5.1.2    Retail Pharmacy 
            8.5.1.3    Online Pharmacy
    8.6    Global Diabetic Neuropathy Treatment Market by Treatment Channel
        8.6.1    Public
        8.6.2    Private
    8.7    Global Diabetic Neuropathy Treatment Market by Region
        8.7.1    Market Overview
            8.7.1.1    North America
            8.7.1.2    Europe 
            8.7.1.3    Asia Pacific
            8.7.1.4    Latin America
            8.7.1.5    Middle East and Africa
9    North America  Diabetic Neuropathy Treatment Market
    9.1    Market Share by Country
    9.2    United States of America
        9.2.1    Historical Trend (2017-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    Canada
        9.3.1    Historical Trend (2017-2023)
        9.3.2    Forecast Trend (2024-2032)
10    Europe Diabetic Neuropathy Treatment Market
    10.1    Market Share by Country
    10.2    United Kingdom
        10.2.1    Historical Trend (2017-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    Germany
        10.3.1    Historical Trend (2017-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    France
        10.4.1    Historical Trend (2017-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Italy
        10.5.1    Historical Trend (2017-2023)
        10.5.2    Forecast Trend (2024-2032)
    10.6    Others
11    Asia Pacific Diabetic Neuropathy Treatment Market
    11.1    Market Share by Country
    11.2    China
        11.2.1    Historical Trend (2017-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    Japan
        11.3.1    Historical Trend (2017-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    India
        11.4.1    Historical Trend (2017-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    ASEAN
        11.5.1    Historical Trend (2017-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Australia
        11.6.1    Historical Trend (2017-2023)
        11.6.2    Forecast Trend (2024-2032)
    11.7    Others
12    Latin America Diabetic Neuropathy Treatment Market
    12.1    Market Share by Country
    12.2    Brazil
        12.2.1    Historical Trend (2017-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Argentina
        12.3.1    Historical Trend (2017-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Mexico
        12.4.1    Historical Trend (2017-2023)
        12.4.2    Forecast Trend (2024-2032)
    12.5    Others
13    Middle East and Africa Diabetic Neuropathy Treatment Market
    13.1    Market Share by Country
    13.2    Saudi Arabia
        13.2.1    Historical Trend (2017-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    United Arab Emirates
        13.3.1    Historical Trend (2017-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    Nigeria
        13.4.1    Historical Trend (2017-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    South Africa
        13.5.1    Historical Trend (2017-2023)
        13.5.2    Forecast Trend (2024-2032)
    13.6    Others
14    Global Diabetic Neuropathy Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model
    14.4    Key Demand Indicator 
    14.5    Key Price Indicator 
    14.6    Industry Events, Initiatives, and Trends  
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Novartis AG
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    Pfizer Inc.
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Glenmark Pharmaceuticals Ltd.
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Eli Lilly and Company
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    Abbott Laboratories 
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    F. Hoffmann-La Roche Ltd
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Johnson & Johnson Services, Inc.
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    GlaxoSmithKline Plc
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications 
    15.9    Lupin Ltd
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications 
    15.10    Depomed, Inc
        15.10.1    Company Overview
        15.10.2    Product Portfolio
        15.10.3    Demographic Reach and Achievements
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications 
    15.11    Astellas Pharma Inc 
        15.11.1    Company Overview
        15.11.2    Product Portfolio
        15.11.3    Demographic Reach and Achievements
        15.11.4    Mergers and Acquisitions
        15.11.5    Certifications
    15.12    Meda Pharma GmBH & Co. KG
        15.12.1    Company Overview
        15.12.2    Product Portfolio
        15.12.3    Demographic Reach and Achievements
        15.12.4    Mergers and Acquisitions
        15.12.5    Certifications
16    Global Diabetic Neuropathy Treatment Market- Drug Distribution Model (Additional Insight)
    16.1    Overview 
    16.2    Potential Distributors 
    16.3    Key Parameters for Distribution Partner Assessment 
17    Payment Methods (Additional Insight)
    17.1    Government Funded
    17.2    Private Insurance
    17.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market growth is likely to be driven by the rising prevalence of Hyperglycemia, which is likely to grow at a CAGR of 3% during the forecast period of 2024-2032.

The rising cases of diabetes and launch of new products are the major factors driving the growth of the market.

North America has been leading the global market due to early adoption of drugs, availability of advanced therapies, and the availability of combination drugs.

The high cost of the product and the availability of alternatives for diabetic neuropathy are hindering the market growth.

The four types of diabetic neuropathy are peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy.

Diabetes causes nerve damage, which is known as diabetic neuropathy. Diabetes-related high blood glucose levels, also known as blood sugar, and high levels of fats in the blood, such as triglycerides, can damage nerves over time.

The signs and symptoms of peripheral neuropathy include numbness, prickling, or tingling in your feet or hands that can spread up into your legs and arms. Sharp, jabbing, throbbing, or burning discomfort Touch sensitivity to the extreme.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER